Page 144 - 南京医科大学自然版

第45卷第10期
·1512 · 南 京 医 科 大 学 学 报 2025年10月

tion and systemic TGFβ blockade in metastatic breast ［54］BAO G，WANG Z，LIU L，et al. Targeting CXCR4/CX⁃
cancer［J］. Clin Cancer Res，2018，24（11）：2493-2504 CL12 axis via［177Lu］Lu ⁃ DOTAGA.（SA.FAPi）2 with
［50］SHI L，SHENG J，WANG M，et al. Combination therapy of CXCR4 antagonist in triple ⁃ negative breast cancer［J］.
TGF⁃β blockade and commensal⁃derived probiotics pro⁃ Eur J Nucl Med Mol Imaging，2024，51（9）：2744-2757
vides enhanced antitumor immune response and tumor ［55］ZHANG G，HE Y，LIU Y，et al. Reduced hyaluronan cross⁃
suppression［J］. Theranostics，2019，9（14）：4115-4129 linking induces breast cancer malignancy in a CAF ⁃
［51］HOLMGAARD R B，SCHAER D A，LI Y，et al. Targeting dependent manner［J］. Cell Death Dis，2021，12（6）：586
the TGFβ pathway with galunisertib，a TGFβRI small ［56］BRUNDEL D H，FEENEY O M，NOWELL C J，et al.
molecule inhibitor，promotes anti⁃tumor immunity leading Depolymerization of hyaluronan using PEGylated human
to durable，complete responses，as monotherapy and in recombinant hyaluronidase promotes nanoparticle tumor
combination with checkpoint blockade［J］. J Immunother penetration［J］. Nanomedicine（Lond），2021，16（4）：275-
Cancer，2018，6（1）：47 292
［52］KNUDSON K M，HICKS K C，LUO X，et al. M7824，a ［57］WAWRZYNIAK D，GRABOWSKA M，GŁODOWICZ P，
novel bifunctional anti⁃PD⁃L1/TGFβ Trap fusion protein， et al. Down⁃regulation of tenascin⁃C inhibits breast can⁃
promotes anti⁃tumor efficacy as monotherapy and in com⁃ cer cells development by cell growth，migration，and adhe⁃
bination with vaccine［J］. Oncoimmunology，2018，7（5）： sion impairment［J］. PLoS One，2020，15（8）：e0237889
e1426519 ［58］DELIGNE C，MURDAMOOTHOO D，GAMMAGE A N，et
［53］EBBING E A，STEINS A，FESSLER E，et al. Esophageal al. Matrix⁃targeting immunotherapy controls tumor growth
adenocarcinoma cells and xenograft tumors exposed to and spread by switching macrophage phenotype［J］.
Erb⁃b2 receptor tyrosine kinase 2 and 3 inhibitors activate Cancer Immunol Res，2020，8（3）：368-382
transforming growth factor beta signaling，which induces ［收稿日期］ 2025-05-29
epithelial to mesenchymal transition［J］. Gastroenterology， （本文编辑：唐 震）
2017，153（1）：63-76.e14

（上接第1442页）

e3001863 to induce cholesterol ⁃ dependent invasion and sorafenib
［21］ SHI Y，ANDHEY P S，ISING C，et al. Overexpressing resistance in hepatocellular carcinoma［J］. Cancer Res，
low ⁃ density lipoprotein receptor reduces tau ⁃ associated 2024，84（11）：1872-1888
neurodegeneration in relation to apoE ⁃ linked mecha⁃ ［25］QIN W H，YANG Z S，LI M，et al. High serum levels of
nisms［J］.Neuron，2021，109（15）：2413-2426.e7 cholesterol increase antitumor functions of nature killer
［22］ TAVAZOIE M F，POLLACK I，TANQUECO R，et al. cells and reduce growth of liver tumors in mice［J］. Gas⁃
LXR/ApoE activation restricts innate immune suppres⁃ troenterology，2020，158（6）：1713-1727
sion in cancer［J］. Cell，2018，172（4）：825-840.e18 ［26］HUI B Q，LU C，LI H Y，et al. Inhibition of APOE potenti⁃
［23］YU S K，QIAN L M，MA J. Comprehensive analysis of the ates immune checkpoint therapy for cancer［J］. Int J Biol
expression and prognosis for APOE in malignancies：a Sci，2022，18（14）：5230-5240
pan⁃cancer analysis［J］. Oncol Res，2022，30（1）：13-22 ［收稿日期］ 2025-02-28
［24］WAN S，HE Q Y，YANG Y，et al. SPARC stabilizes ApoE （本文编辑：蒋 莉）